Ningyu Garden, bedroom.
Zhang Ningxi was watching a TV series, and Si Mingyu rested his head on her legs and replied to messages on his phone.
After leaving the Medical Research Institute, Lin Shirui returned to her own residence. It would be okay if she acted crazy once in a while, but how could she do that every night?
The second-generation group chats were full of complaints about Si Mingyu's "absence of group activities." The point was, he didn't have the time to spare. Not to mention the numerous issues at the group company, he had to visit all the branches at least once a month, and he also had to fly to Hong Kong two or three times a month to handle matters related to East Asia Mingyu Hongming Industrial.
Now that he has become more famous, he is invited to participate in more activities. They are all organized by business tycoons, and most of them are not in Shanghai. It would be inappropriate not to go, and it would take a whole day to go. This is on the premise that he has a private jet that can go back and forth on the same day.
Besides, the six people in the group didn't think about what activities they had planned. After seeing Si Mingyu's circle of friends on his trip to Sanya, they also thought about renting a yacht and taking a group of young ladies to recreate the classic scene.
It would be fine if you were closer, but if you were so far away, Si Mingyu didn't think he could hide this from his wife. So he righteously refused, saying that he had just returned and didn't want to go again.
"Wife." Si Mingyu rubbed his head against Zhang Ningxi's leg.
"Don't move, it's itchy, tell me what you want to say."
"My wife is so beautiful."
"Keep praising, don't stop." Zhang Ningxi touched his head.
"Uh." It seems that the script is not like this.
Baji, his wife kissed him on the face: "That's enough, tell me what you want to say."
"Yeah, yeah. I plan to take control of Peacock Feather Company."
"Any new plans?" Zhang Ningxi knew that Si Mingyu never did useless work.
"The pharmaceutical research institute used to be relatively low-key, but now, with half of its new drug development successful, it has attracted attention from all sides. Cosmetics and pharmaceuticals are both chemical-related, so they can actually collaborate on R&D, using the success of the pharmaceutical research institute to endorse and promote cosmetics."
"That's a good idea."
The main focus of cosmetics is the effect after use. No matter what the actual effect is, consumers must believe that it is really effective.
Once the pharmaceutical research institute's drug is on the market, we can use the joint R&D initiative to promote a blockbuster cosmetics product. We'll then announce, "Look, these researchers have conquered even such a difficult disease. Our company, in collaboration with this institute, has developed this product, containing a rare ingredient, extracted using technology, to combat [X] and enhance [X], and it's incredibly effective."
This is all about marketing. As long as people believe in it and buy it, it's all fine. It's all my own business, and there's no extra cost. Even if it doesn't succeed, increasing my stake in Peacock Feather Cosmetics based on their performance isn't a loss.
"Then it's settled. You will be the chairman of the board then, wife."
Si Mingyu picked up the phone and called Wang Qinqin.
"Hello, Mr. Si, how can I help you?" Wang Qinqin, who provided 24-hour dedicated service to Si Mingyu, answered the call immediately.
"I'm planning to acquire 30% of Peacock Feather Cosmetics' shares. I'll borrow the money from China Merchants Bank, using your bank's stock as collateral. I'll borrow as much as I need. The group's financial director will be in touch with you on the details."
"OK."
Si Mingyu then called Bian Guohai and Lu Jiamei, the asset management company's manager, separately, asking the former to handle the loan and the latter to acquire the shares. Aside from the circulating shares, the remaining shares were held by various shareholders, and they would need to be negotiated individually. If the premium was high enough, someone would be willing to transfer.
The loan amount depends on your final expenses. Once the loan agreement is signed, the loan can be disbursed; the review process is just a formality. There's no more reliable collateral than using CMB stock as collateral to get a loan from CMB.
So-called rare diseases are those with an incidence rate of less than one in ten thousand newborns, a prevalence rate of less than one in ten thousand, and a total number of patients less than one hundred and fourteen thousand.
So how expensive are drugs for rare diseases?
Developed by Swiss pharmaceutical company Novartis, this drug is used to treat spinal muscular atrophy. The price of one dose of the drug was US$2.1 million at the time.
Also developed by Novartis Pharmaceuticals in Switzerland, it was used to treat periodic fever syndromes, including tumor necrosis factor receptor-associated periodic syndrome, protein-associated periodic syndrome, and familial Mediterranean fever. Its annual price tag was $370,000. Yes, that's a lot of money to spend annually just for treatment.
Si Mingyu invested more than 13 billion yuan in research and development expenses in the early stage and started the research and development of four drugs. Three of them were successful and one failed, resulting in a loss of more than 2 billion yuan.
If the subsequent clinical trials were conducted in China, it would require an investment of more than 10 billion yuan. However, if it were conducted in India, more than half of the cost could be saved, and only more than 4 billion yuan would be needed.
One of the three successful new drugs treats a rare disease. Even at a price of one million Chinese yuan per dose, it would have to sell 700 doses to break even. The other two treat common chronic diseases. For these, a small profit margin and high volume are sufficient. Of course, this so-called small profit margin is relative to the previous drug.
The Fifty States Federation does not have holidays during the Spring Festival, so with the incentive of the bonus, the head of the research institute there completed the procedures for conducting clinical trials in India in the shortest time possible. Over there, as long as you have money, everything is not a problem.
A group of researchers and related personnel then happily traveled to India with the supplies needed for the clinical trial and their travel allowance. This kind of thing has already become an "industry" there, so their workload was not heavy; it was basically like a trip.
With the start of clinical trials, patients with these rare diseases around the world immediately took notice. For them, this is a life-saving device, and once the first and second phases of clinical trials are successfully completed, some will not even wait for the start of the third phase to take action.
Because they can't wait any longer, taking a small risk is nothing compared to their lives, and there are many people who think this way. Yes, the proportion of patients with rare diseases is indeed small, but that is based on the world's population.
As for the two medicines for treating chronic diseases, there is no need to rush, just take your time.
Furthermore, after discussing this with Li Zhenyuan, Si Mingyu launched research and development projects for four new drugs. While the R&D costs were high, they didn't require a one-time investment. The annual R&D costs of four drugs, at $400 million, were equivalent to just over 2.5 billion Chinese yuan, which could be fully covered by the revenue from the natural gas transported by LNG ships.
It is true that the increase in European natural gas inventories has led to a sharp drop in prices, and the insufficient unloading capacity of ports has resulted in LNG ships being unable to unload for a long time, which has greatly increased costs. However, because of his special channels, Si Mingyu can still earn 1 billion Chinese yuan per month.
Besides, as long as the medical research institute waits for a year for new drugs to treat rare diseases to be launched on the market, it can be completely self-sufficient.
Continue read on readnovelmtl.com
